MODERN APPROACHES IN THE TREATMENT OF DYSLIPIDEMIA AND FUTURE PERSPECTIVES

Abstract

Dyslipidemia, defined as an elevated level of total low-density lipoprotein-cholesterol (LDL-C) (<90 percentile), or high-density lipoprotein-cholesterol (HDL-C), occupies one of the main places among metabolic disorders. or reduced levels of apoprotein A-1 (<10 percentile). The reduction of cholesterol and especially its atherogenic fraction DSP is focused on the identification of proteins involved in cholesterol endo and exosynthesis. Aim of the study: to show that, despite the widely studied and widely recognized use of statins in the treatment of dyslipidemia, the "gold standard" is pharmacologically recognized. Materials and Methods: Dyslipidemia has become a major problem in the civilized world. The paper details researches on the possibilities of managing low-density lipoproteins. Since the discovery of compactin, the dominant effectiveness of statins in the treatment of dyslipidemia has been proven. Available, innovative and will be able to reduce cholesterol and especially its atherogenic fraction DSP, focused on the identification of proteins involved in endo and exosynthesis of cholesterol. Conclusion: approaches to the treatment of dyslipidemia have changed significantly. The use of probucol has been practically stopped. Nicotinic acid has been significantly reduced. According to the recommendations of ESC/EAK and AHA/ACC, the first-line drugs for lowering LHL-C levels are statins, and drugs that reduce cholesterol absorption from the intestines - Ezetims are also a priority. Sequestrants of bile acids - cholestyramine and others, and in the case of familial hypercholesterolemia - monoclonal antibodies. When choosing a drug for PCSK-9 (Evolokumab and others), we should take into account the potential cost-benefit of treatment, some groups, for example, statins are cheaper than new drugs. However, new drugs in certain patient populations (as opposed to those with familial hypercholesterolemia) may be more effective in lowering LHL-c levels.